Interleukin-1 signaling pathway (IL-1 pathway)

The "Interleukin‑1 synthesis pathway" is not a single molecule or receptor but rather refers to the complex biological process by which interleukin‑1 (IL‑1) family cytokines are produced and signal within the body. The IL‑1 family includes key pro-inflammatory cytokines such as interleukin‑1 alpha (IL‑1α) and interleukin‑1 beta (IL‑1β), which play central roles in mediating immune responses and inflammation[2][4]. These cytokines are synthesized as precursors that require specific processing to become active; for example, IL‑1β must be cleaved by caspase‑1 following activation by danger signals[2]. The mature forms of these cytokines bind to the interleukin 1 receptor type I (IL–1RI), triggering downstream inflammatory signaling cascades[2][4]. Dysregulation of this pathway is implicated in various diseases characterized by excessive inflammation or autoimmunity. While drugs can target components of this pathway—such as blocking the activity of IL–1 itself—the "synthesis pathway" is not a discrete drug target but rather a collection of molecular events involving multiple proteins and regulatory steps[2][4]. **Note:** This entry describes a *pathway*, not an individual therapeutic target like a receptor or enzyme. For structured data on drug targets, it would be more appropriate to focus on specific molecules within this pathway, such as "Interleukin 1 beta" or "Interleukin 1 receptor type I"[2][3].

Other names

IL-1 synthesis pathwayInterleukin-1 pathwayIL-1 signaling cascade